Cerus Websites

INTERCEPT® Goes Beyond

INTERCEPT® Blood System for Platelets Pathogen Reduction System

INTERCEPT® Blood System for Cryoprecipitation

for the manufacture of Pathogen Reduced Cryoprecipitated Fibrinogen Complex

INTERCEPT goes beyond to protect patients*, improve availability, and deliver value.

The INTERCEPT Blood System protects patients through broad-spectrum transfusion-transmitted infection (TTI) risk reduction with the inactivation of bacteria, viruses, protozoans, and leukocytes.1,2 Blood components are available earlier, resulting in fresher platelets that may be transfused sooner3,4 , and improving availability of fibrinogen† and other vital clotting factors when minutes matter.5 Economic and operational efficiencies are gained through waste and cost reduction associated with testing and TTI risks.6-8

*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts.
†INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; and when stored frozen requires thawing prior to use.

INTERCEPT® Blood System for Platelets

Pathogen Reduction System

Pathogen Reduction System
Learn More
Pathogen Reduced Cryoprecipitated Fibrinogen Complex

INTERCEPT® Fibrinogen Complex (IFC)

INTERCEPT Fibrinogen Complex (IFC)
Learn More

What’s New

Valley Children’s IFC case study

Case Study: Implementing the Use of INTERCEPT Fibrinogen Complex

Valley Children’s Hospital in Modesto, California was experiencing high wastage rates using cryo AHF 5-pools, adversely impacting their transfusion budget. After implementation of IFC for the treatment of bleeding associated with fibrinogen deficiency, Valley Children’s was able to significantly reduce their wastage, meeting their target wastage rate and experiencing significant cost savings.

Read Case Study

Learn More

INTERCEPT Goes Beyond

Portfolio Brochure

Targeting DNA and RNA to Prevent Pathogen Proliferation. A proactive approach to blood safety through reduction of a broad range of pathogens

Mechanism of Action Brochure

INTERCEPT Goes Beyond

Protect Patients*

Improve Availability

Deliver Value

*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

  1. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
  2. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert.
  3. Collier, T. and Chrebtow , V. “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience”. Cerus Corporation. AABB 2022. Poster P-IV-8.
  4. Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs. LVDS Screened Platelets.” OneBlood. AABB 2022. Poster P-IV-2.
  5. Meyer DE, et al. The Journal of Trauma and Acute Care Surgery 2017;83:19-24.
  6. Harm SK, et al. Transfusion. 2018 Apr; 58(4):938-942.
  7. Ruby KN, et al. Transfusion. 2018 Jul; 58(7):1665-1669.
  8. Cerus Corporation. (2022) “Assessing Impact of INTERCEPT Fibrinogen Complex (IFC) on Wastage and Massive Transfusion Protocols (MTPs)”. [Case Study].